(37) to Propafenone bradycardia (<50 dofetilide, and 21 of 41 as (n=41) bpm), AV block, propafenone, (51%) treated propafenone and prolonged QTc, MI, and placebo w/ propafenone as an placebo unstable angina, had a 50%, reported no alternative in the recent sudden death, 54%, and 6% adverse events. therapeutic hematologic probability, option for the of /hepatic/renal respectively, No significant treatment of PSVT disease of remaining differences pts w/ PSVT. free of were noted episodes of between 3 Limited in that PSVT (p<.001 groups in PSVTs not for both incidence of specified. dofetilide and propafenone adverse vs. placebo). events or adverse The hazard events (p=0.73 ratio for and p=0.74, dofetilide vs. respectively). placebo was 0.33 (95% CI: 0.18-0.61), and the hazard ratio for propafenone vs. placebo was 0.27 (95% CI: Of 40 pts treated w/ dofetilide and propafenone, 23 (58%) and 25 (61%) had no recurring PSVT, compared w/ 16 (39%) in placebo group. Catheter Therapy (including cyroablation vs. RFA studies) Slow vs. 50 Anterior Posterior AVNRT None stated Primary One pt w/ N/A N/A Posterior JJ fast path (n=22) (n=28) success rates, RBBB during (slow path) 1993 ablation Up to 1 h or anterior vs. an anterior approach to (116) for 10 RF Up to 1 h or posterior lesion RF
(37) to and placebo in the of PSVT Propafenone (n=41) bradycardia (<50 bpm), AV block, prolonged QTc, MI, unstable angina, recent sudden death, hematologic /hepatic/renal disease dofetilide, propafenone, and placebo had a 50%, 54%, and 6% probability, respectively, of remaining free of episodes of PSVT (p<.001 for both dofetilide and propafenone vs. placebo). The hazard ratio for dofetilide vs. placebo was 0.33 (95% CI: 0.18-0.61), and the hazard ratio for propafenone vs. placebo was 0.27 (95% CI: Of 40 pts treated w/ dofetilide and propafenone, 23 (58%) and 25 (61%) had no recurring PSVT, compared w/ 16 (39%) in placebo group. and 21 of 41 (51%) treated w/ propafenone reported no adverse events. No significant differences were noted between 3 groups in incidence of adverse events or adverse events (p=0.73 and p=0.74, respectively). as propafenone as an alternative therapeutic option for the treatment of pts w/ PSVT. Limited in that PSVTs not specified. Catheter Therapy (including cyroablation vs. RFA studies) JJ 1993 (116) Slow vs. fast path ablation for 50 Anterior (n=22) Up to 1 h or 10 RF Posterior (n=28) Up to 1 h or AVNRT None stated Primary success rates, anterior vs. posterior One pt w/ RBBB during an anterior lesion N/A N/A Posterior (slow path) approach to RF
2015_SVT_Evidence_Tables_Data_Supplement.docx